Claims
- 1. A pharmaceutical composition comprising a carrier and a crosslinked, water insoluble polyallylamine homopolymer, wherein said polyallylamine homopolymer comprises repeat units represented by the structural formula:
- 2. The pharmaceutical composition of claim 1, wherein said polyallylamine homopolymer is crosslinked with an epichlorohydrin crosslinking agent.
- 3. The pharmaceutical composition of claim 2, wherein the amount of said crosslinking agent is about 2% to about 20% by weight of the polymer.
- 4. The pharmaceutical composition of claim 1, wherein said polyallylamine homopolymer is fully or partially protonated.
- 5. The pharmaceutical composition of claim 4, wherein said polyallylamine homopolymer is protonated with HCl.
- 6. The pharmaceutical composition of claim 5, wherein said polyallylamine homopolymer is partially protonated.
- 7. The pharmaceutical composition of claim 1, wherein said pharmaceutical composition consists essentially of one or more carriers and said polyallylamine homopolymer.
- 8. The pharmaceutical composition of claim 1, wherein said pharmaceutical composition consists of one or more carriers and said polyallylamine homopolymer.
- 9. The pharmaceutical composition of claim 1, wherein said pharmaceutical composition is in the form of a tablet or a capsule.
- 10. A method for removing phosphate from a patient, comprising orally administering to said patient a therapeutically effective amount of a composition comprising a crosslinked, water insoluble polyallylamine homopolymer, wherein said polyallylamine homopolymer comprises repeat units represented by the structural formula:
- 11. The method of claim 10, wherein said polyallylamine homopolymer is crosslinked with an epichlorohydrin crosslinking agent.
- 12. The method of claim 11, wherein the amount of said crosslinking agent is about 2% to about 20% by weight of the polymer.
- 13. The method of claim 10, wherein said polyallylamine homopolymer is fully or partially protonated.
- 14. The method of claim 13, wherein said polyallylamine homopolymer is protonated with HCl.
- 15. The method of claim 14, wherein said polyallylamine homopolymer is partially protonated.
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. Ser. No. 10/322,904, filed Dec. 17, 2002, which is a continuation of U.S. Ser. No. 09/542,329, filed Apr. 4, 2000, now U.S. Pat. No. 6,509,013, which is a continuation of U.S. Ser. No. 08/929,784, filed Sep. 15, 1997, now U.S. Pat. No. 6,083,495, which is a divisional of U.S. Ser. No. 08/471,747, filed Jun. 6, 1995, now U.S. Pat. No. 5,667,775, which is a continuation-in-part of U.S. Ser. No. 08/238,458, filed May 5, 1994, now U.S. Pat. No. 5,496,545, which is a continuation-in-part of U.S. Ser. No. 08/105,591, filed Aug. 11, 1993, now abandoned, the entire teachings of which are incorporated herein by reference.
Divisions (1)
|
Number |
Date |
Country |
Parent |
08471747 |
Jun 1995 |
US |
Child |
08929784 |
Sep 1997 |
US |
Continuations (3)
|
Number |
Date |
Country |
Parent |
10322904 |
Dec 2002 |
US |
Child |
10766638 |
Jan 2004 |
US |
Parent |
09542329 |
Apr 2000 |
US |
Child |
10322904 |
Dec 2002 |
US |
Parent |
08929784 |
Sep 1997 |
US |
Child |
09542329 |
Apr 2000 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
08238458 |
May 1994 |
US |
Child |
08471747 |
Jun 1995 |
US |
Parent |
08105591 |
Aug 1993 |
US |
Child |
08238458 |
May 1994 |
US |